EP2036549B1 - Novel Composition - Google Patents

Novel Composition Download PDF

Info

Publication number
EP2036549B1
EP2036549B1 EP08166881A EP08166881A EP2036549B1 EP 2036549 B1 EP2036549 B1 EP 2036549B1 EP 08166881 A EP08166881 A EP 08166881A EP 08166881 A EP08166881 A EP 08166881A EP 2036549 B1 EP2036549 B1 EP 2036549B1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
pvp
formoterol
composition according
budesonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP08166881A
Other languages
German (de)
French (fr)
Other versions
EP2036549A1 (en
Inventor
Nayna Govind
Maria Marlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20286853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2036549(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to SI200331805T priority Critical patent/SI2036549T1/en
Publication of EP2036549A1 publication Critical patent/EP2036549A1/en
Application granted granted Critical
Publication of EP2036549B1 publication Critical patent/EP2036549B1/en
Priority to CY20101100546T priority patent/CY1110081T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a formulation comprising formoterol and budesonide for use in the treatment of inflammatory conditions/disorders, especially respiratory diseases such as asthma, COPD and rhinitis.
  • Stability is one of the most important factors which determines whether a compound or a mixture of compounds can be developed into a therapeutically useful pharmaceutical product.
  • EP 0 534 731 discloses pressurised aerosol compositions comprising a liquefied hydrofluoroalkane, a powdered medicament dispersible therein and a polymer soluble in the liquefied hydrofluoroalkane, wherein the polymer includes recurring structural units, the units being selected from amides containing units and carboxylic acid ester containing units.
  • US 6,004,537 discloses aerosol formulations containing budesonide, formoterol, at least one fluoroalkane propellant, and a cosolvent present in an amount that dissolves or solubilizes the budesonide, formoterol in the mixture of cosolvent and propellant.
  • WO 01/78693 discloses dry powder compositions containing one or more active ingredients in micronised form selected from budesonide, formoterol and TA 2005.
  • WO 02/03958 discloses an aerosol formulation suitable for inhalation comprising an active substance, an aerosol propellant, a polar fluorinated molecule and an excipient.
  • WO 98/21175 discloses a method for the preparation of optically pure isomers of formoterol.
  • a pharmaceutical composition comprising formoterol, budesonide, HFA 227, PVP and PEG characterised in that the PVP is present from about 0.0005 to about 0.03 %w/w and the PEG is present from about 0.05 to about 0.3 5% w/w.
  • the PVP is present in an amount of 0.001 % w/w.
  • the PVP is PVP K25.
  • the PEG is present in an amount of 0.3 % w/w.
  • the PEG is PEG 1000.
  • concentrations of formoterol/budesonide are such that the formulation delivers formoterol/budesonide at 4.5/40 mcg, 4.5/80 mcg, 4.5/160 mcg or 4.5/320mcg per actuation.
  • the formoterol can be in the form of a mixture of enantiomers.
  • the formoterol is in the form of a single enantiomer, preferably the R, R enantiomer.
  • the formoterol can be in the form of the free base, salt or solvate, or a solvate of a salt, preferably the formoterol is in the form of its fumarate dihydrate salt.
  • physiologically salts that can be used include chloride, bromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, benzenesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricaballate, hydroxynapaphthalenecarboxylate or oleate.
  • the second active ingredient is budesonide, including epimers, esters, salts and solvates thereof. More preferably the second active ingredient is budesonide or an epimer thereof, such as the 22R-epimer of budesonide.
  • compositions according to the invention can be used for the treatment or prophylaxis of a respiratory disorder, in particular the treatment or prophylaxis of asthma, rhinitis or COPD.
  • the invention provides a method of treating a respiratory disorder, in particular asthma, rhinitis or COPD, in a mammal, which comprises administering to a patient a pharmaceutical composition as herein defined.
  • a respiratory disorder in particular asthma, rhinitis or COPD
  • compositions of the invention can be inhaled from any suitable MDI device. Doses will be dependent on the severity of the disease and the type of patient, but are preferably 4.5/80 mcg or 4.5/160 mcg per actuation as defined above.
  • the concentration of PVP (0.001 %w/w) used in this formulation has been found to give consistently stable formulations over the required dose range, incorporating a wide range of concentrations of the active components, and at a much lower concentration than indicated in the prior art.
  • OSCAR Optical suspension characterisation
  • TURBISCAN Optical suspension characterisation
  • Optical Suspension Characterisation (OSCAR) equipment is custom designed for the rapid and reproducible semi-quantification of metered dose inhaler suspension characteristics.
  • the OSCAR equipment utilises changes in light transmission with time, to characterise a pre-agitated suspension formulation (a schematic diagram of the equipment is shown in Figure 1 ).
  • the equipment consists of a twin headed test assembly. The head on the left side of the equipment is used with dilute suspensions and the right for concentrated suspensions.
  • the selector switch mounted between the two test heads is used to alternate concentration choice.
  • the output from the selected test head is directed to the equipment mounted voltage display and to the computer for data logging.
  • the analogue signals from photodetectors are digitised and the values collected in data files, these are then processed using a suitable software package.
  • the upper and lower photodetectors are height adjustable and a position readout display is provided to indicate the set height for each test run.
  • the Reagecon Turbidity standards (2500-4000 NTU) are used to calibrate the sensitivity of the OSCAR equipment.
  • the 3000 NTU turbidity calibration standard is used as a standard calibration check.
  • any of the turbidity standards can be used to adjust the sensitivity of the probes to a specific voltage appropriate to the formulation.
  • Turbiscan MA 2000 is a concentrated dispersion and emulsion stability and instability analyser, or a vertical scan macroscopic analyser. It consists of a reading head moving along a flat-bottomed, 5ml cylindrical glass cell, which takes readings of transmitted and backscattered light every 40 ⁇ m on a maximum sample height of 80mm. The scan can be repeated with a programmable frequency to obtain a macroscopic fingerprint of the sample.
  • the profile obtained characterises the samples homogenieity, concentration and mean particle diameter. It allows for quantification of the physical processes the sample is undergoing. As well as detecting destabilisation, Turbiscan allows comparison of, for example, the sedimentaion rate of different suspensions.
  • Turbiscan may be used in several modes, eg transmitted or backscattering modes. Turbiscan has been used here in these examples to measure the transmitted light as a funtion of time
  • Dispersion instability is the result of two physical processes: a) particle size increases as a result of the formation of aggregates, due to flocculation b) particle migration resulting in creaming or sedimentation.
  • a product is stable (ie no flocculation, creaming or sedimentation)
  • the transmitted and backscattered light will remain constant i.e. scans of these will show a constant level profile. If the product undergoes changes in particle size, variations in the transmitted/ backscattered light show as change in the direction of the scan from horizontal or steady state profile.
  • a cell capable of handling pressurised samples is required. Such a cell was used for the evaluations of these HFA formulations. The scans were performed in the AUTO mode. The % transmission averages shown in the figure (see later) were taken from a zone around the middle of the suspension sample.
  • Formulations containing formoterol fumarate dihydrate, budesonide, 0.001% w/w PVP K25 and either 0.1 % w/w or 0.3% PEG 1000 in HFA-227 were prepared in polyethylene terephlate (PET) bottles crimped with a continuous valve.
  • PET polyethylene terephlate
  • the formoterol fumurate dihydrate concentration remained constant at 0.09mg/ml (equivalent to 4.5 mcg formoterol fumurate dihydrate per actuation) and the budesonide concentration varied between approximately 1mg/ml to 8 mg/ml (equivalent to 40 mcg to 320 mcg per actuation).
  • OSCAR analysis of these formulations gave relatively low light transmittance values at the lower sensor, which is indicative of stable suspensions with low flocculation characteristics. Early indications were that the 0.001% w/w PVP with 0.3% PEG 1000 would give the best suspension.
  • FURTHER EVALUATION various concentrations of PVP K25 with a constant PEG 1000 concentration of 0.3% w/w.
  • OSCAR, Turbiscan and photographic methods were used to evaluate the formulations. OSCAR and Turbiscan techniques have been described earlier. Samples with varying concentrations of PVP were analysed to determine suspension stability over time.
  • Figures 9 , 10 and 11 show Budesonide 160 ⁇ g/shot, Formoterol 4.5 ⁇ g/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 15, 30, and 60 seconds standing time.
  • Figures 12 , 13 and 14 shows Budesonide 80 ⁇ g/shot, Formoterol 4.5 ⁇ g/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 30, and 60 seconds standing time.
  • OSCAR DATA Graphs of light transmission versus time
  • FIG. 2 shows the average OSCAR transmission readings (lower sensor only) for various concentrations of PVP K25.
  • a low transmission reading indicates that the suspension is dispersed preventing light being transmitted. Hence, it can be seen that the lowest line is the most stable formulation. This is the 0.001% PVP sample.
  • Figures 5 and 6 show that the suspension with 0.001% w/w PVP is the most stable (bottom bold line) with the lowest % transmission.
  • FURTHER EVALUATION Determination of the optimum PEG 1000 concentration.
  • Force to fire testing was performed using the Lloyd LRX testing machine.
  • the pMDI unit to be tested was placed valve down in a can holder on the lower platform of the unit.
  • the upper crosshead was then moved to just above the base of the can.
  • Can actuations were performed using a standard protocol.
  • force data is captured by means of the load cell located at the top of the upper crosshead.
  • This program was designed to output the return force at 0.5mm stem return as this is the point at which the metering chamber is considered to refill.
  • a low return force is indicative of high friction and potential sticking problems. It also suggests there may be a problem with low actuation weights as the propellant enters the metering chamber more slowly and has time to vaporise.
  • Force to fire testing was performed at preset actuations.
  • Figure 7 shows the effect of PEG 1000 concentration on stem return force for the 4.5/160 ⁇ g formoterol/budesonide formulation
  • the Turbiscan data shows that there is little difference between the stability of suspensions made with varying levels of PEG 1000 except for the 0.005% w/w level which was unsatisfactory.
  • Figures 15 and 16 show Budesonide 80 ⁇ g/shot, Formoterol 4.5 ⁇ g/shot with 0.001% PVP K25 and various concentrations of PEG 1000 at 0 (1) and 10 minutes (2) standing time

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Networks Using Active Elements (AREA)

Abstract

The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases

Description

    Field of the invention
  • The present invention relates to a formulation comprising formoterol and budesonide for use in the treatment of inflammatory conditions/disorders, especially respiratory diseases such as asthma, COPD and rhinitis.
    • Background of the invention
  • Stability is one of the most important factors which determines whether a compound or a mixture of compounds can be developed into a therapeutically useful pharmaceutical product.
  • Combinations of formoterol and budesonide are known in the art, see for example WO 93/11773 discloses such a combination that is now marketed as Symbicort® in a dry powder inhaler. There are a variety of other inhalers by which a respiratory product can be administered, such as pressurised metered dose inhalers (pMDI's). Formulations for pMDI's may require certain excipients as disclosed in WO 93/05765 .
  • EP 0 534 731 discloses pressurised aerosol compositions comprising a liquefied hydrofluoroalkane, a powdered medicament dispersible therein and a polymer soluble in the liquefied hydrofluoroalkane, wherein the polymer includes recurring structural units, the units being selected from amides containing units and carboxylic acid ester containing units.
  • US 6,004,537 discloses aerosol formulations containing budesonide, formoterol, at least one fluoroalkane propellant, and a cosolvent present in an amount that dissolves or solubilizes the budesonide, formoterol in the mixture of cosolvent and propellant.
  • WO 01/78693 discloses dry powder compositions containing one or more active ingredients in micronised form selected from budesonide, formoterol and TA 2005. WO 02/03958 discloses an aerosol formulation suitable for inhalation comprising an active substance, an aerosol propellant, a polar fluorinated molecule and an excipient.
  • WO 98/21175 discloses a method for the preparation of optically pure isomers of formoterol.
  • It has now been found that certain HFA formulations comprising formoterol and budesonide together with polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG) exhibit excellent physical suspension stability.
    • Description of the invention
  • In accordance with the present invention, there is provided a pharmaceutical composition comprising formoterol, budesonide, HFA 227, PVP and PEG characterised in that the PVP is present from about 0.0005 to about 0.03 %w/w and the PEG is present from about 0.05 to about 0.3 5% w/w.
  • Preferably the PVP is present in an amount of 0.001 % w/w. Preferably the PVP is PVP K25.
  • Preferably the PEG is present in an amount of 0.3 % w/w. Preferably the PEG is PEG 1000.
  • Preferably the concentrations of formoterol/budesonide are such that the formulation delivers formoterol/budesonide at 4.5/40 mcg, 4.5/80 mcg, 4.5/160 mcg or 4.5/320mcg per actuation.
  • The formoterol can be in the form of a mixture of enantiomers. Preferably the formoterol is in the form of a single enantiomer, preferably the R, R enantiomer. The formoterol can be in the form of the free base, salt or solvate, or a solvate of a salt, preferably the formoterol is in the form of its fumarate dihydrate salt. Other suitable physiologically salts that can be used include chloride, bromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, benzenesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricaballate, hydroxynapaphthalenecarboxylate or oleate.
    Preferably the second active ingredient is budesonide, including epimers, esters, salts and solvates thereof. More preferably the second active ingredient is budesonide or an epimer thereof, such as the 22R-epimer of budesonide.
  • The pharmaceutical compositions according to the invention can be used for the treatment or prophylaxis of a respiratory disorder, in particular the treatment or prophylaxis of asthma, rhinitis or COPD.
  • In a further aspect the invention provides a method of treating a respiratory disorder, in particular asthma, rhinitis or COPD, in a mammal, which comprises administering to a patient a pharmaceutical composition as herein defined.
  • The compositions of the invention can be inhaled from any suitable MDI device. Doses will be dependent on the severity of the disease and the type of patient, but are preferably 4.5/80 mcg or 4.5/160 mcg per actuation as defined above.
  • The concentration of PVP (0.001 %w/w) used in this formulation has been found to give consistently stable formulations over the required dose range, incorporating a wide range of concentrations of the active components, and at a much lower concentration than indicated in the prior art.
  • The invention is illustrated by the following examples.
    • Experimental section
  • Two methods can be used to evaluate physical suspension stability: Optical suspension characterisation (OSCAR), and TURBISCAN. Both methods are used to semi-quantify sedimentation/creaming rates. OSCAR measurements are performed using the PET bottles directly. For TURBISCAN analysis, the suspensions are transferred to custom designed pressure cells for measurement of light transmittance and backscattering.
    • METHODOLOGY OSCAR
  • Optical Suspension Characterisation (OSCAR) equipment is custom designed for the rapid and reproducible semi-quantification of metered dose inhaler suspension characteristics.
  • The OSCAR equipment utilises changes in light transmission with time, to characterise a pre-agitated suspension formulation (a schematic diagram of the equipment is shown in Figure 1). The equipment consists of a twin headed test assembly. The head on the left side of the equipment is used with dilute suspensions and the right for concentrated suspensions. The selector switch mounted between the two test heads is used to alternate concentration choice. The output from the selected test head is directed to the equipment mounted voltage display and to the computer for data logging. The analogue signals from photodetectors are digitised and the values collected in data files, these are then processed using a suitable software package. There are two equipment mounted voltage displays, one each for the upper and lower photodetectors. The upper and lower photodetectors are height adjustable and a position readout display is provided to indicate the set height for each test run.
  • The Reagecon Turbidity standards (2500-4000 NTU) are used to calibrate the sensitivity of the OSCAR equipment. In this case, the 3000 NTU turbidity calibration standard is used as a standard calibration check. However any of the turbidity standards can be used to adjust the sensitivity of the probes to a specific voltage appropriate to the formulation.
  • Samples for test on the OSCAR equipment are presented in PET bottles crimped with non-metering valves.
  • For background information and prior art for this method refer to papers from Drug Delivery to the Lungs 1X, 1997, Method Development of the OSCAR technique for the characterization of metered dose inhaler formulations, Authors N. Govind, P. Lambert And Drug delivery to the Lungs VI, 1995, A Rapid Technique for Characterisation of the Suspension Dynamics of metered Dose Inhaler Formulations, Author, PA Jinks (3M Healthcare Ltd)
    • TURBISCAN
  • Turbiscan MA 2000 is a concentrated dispersion and emulsion stability and instability analyser, or a vertical scan macroscopic analyser. It consists of a reading head moving along a flat-bottomed, 5ml cylindrical glass cell, which takes readings of transmitted and backscattered light every 40 µm on a maximum sample height of 80mm. The scan can be repeated with a programmable frequency to obtain a macroscopic fingerprint of the sample.
  • The reading head uses a pulsed near infrared light source (wavelength = 850 nm) and two synchronous detectors:
    • Transmission detector: Picks up light transmitted through the solution in the tube, at 0°
    • Backscattering detector: Receives the light back scattered by the product at 135°.
  • The profile obtained characterises the samples homogenieity, concentration and mean particle diameter. It allows for quantification of the physical processes the sample is undergoing. As well as detecting destabilisation, Turbiscan allows comparison of, for example, the sedimentaion rate of different suspensions.
  • Turbiscan may be used in several modes, eg transmitted or backscattering modes. Turbiscan has been used here in these examples to measure the transmitted light as a funtion of time
  • Dispersion instability is the result of two physical processes: a) particle size increases as a result of the formation of aggregates, due to flocculation b) particle migration resulting in creaming or sedimentation. When a product is stable (ie no flocculation, creaming or sedimentation), the transmitted and backscattered light will remain constant i.e. scans of these will show a constant level profile. If the product undergoes changes in particle size, variations in the transmitted/ backscattered light show as change in the direction of the scan from horizontal or steady state profile.
    For pressurised systems a cell capable of handling pressurised samples is required. Such a cell was used for the evaluations of these HFA formulations. The scans were performed in the AUTO mode.
    The % transmission averages shown in the figure (see later) were taken from a zone around the middle of the suspension sample.
    • INITIAL EVALUATION
  • For the initial evaluation, only OSCAR was used.
  • Formulations containing formoterol fumarate dihydrate, budesonide, 0.001% w/w PVP K25 and either 0.1 % w/w or 0.3% PEG 1000 in HFA-227 were prepared in polyethylene terephlate (PET) bottles crimped with a continuous valve. For all formulations, the formoterol fumurate dihydrate concentration remained constant at 0.09mg/ml (equivalent to 4.5 mcg formoterol fumurate dihydrate per actuation) and the budesonide concentration varied between approximately 1mg/ml to 8 mg/ml (equivalent to 40 mcg to 320 mcg per actuation).
    • Early OSCAR data for Symbicort pMDI formulations
  • Figure imgb0001
  • OSCAR analysis of these formulations gave relatively low light transmittance values at the lower sensor, which is indicative of stable suspensions with low flocculation characteristics. Early indications were that the 0.001% w/w PVP with 0.3% PEG 1000 would give the best suspension.
  • FURTHER EVALUATION: various concentrations of PVP K25 with a constant PEG 1000 concentration of 0.3% w/w.
  • OSCAR, Turbiscan and photographic methods were used to evaluate the formulations. OSCAR and Turbiscan techniques have been described earlier. Samples with varying concentrations of PVP were analysed to determine suspension stability over time.
    • PHOTOGRAPHIC ANALYSIS
  • For the photographic analysis, samples were prepared in PET bottles and photographed digitally over time, using a black background. These photographs (some of which are shown here) show the behaviour of the suspension over time and allow easy comparison of the effectiveness of the various concentrations of PVP. The concentration of PVP varied from 0.0001 to 0.05 % w/w. From left to right on the photographs the concentration of PVP is as follows:
    0.0001 far left 0.0005 0.001 0.01 0.03 0.05 far right
    • DIGITAL PHOTOGRAPHY OF FORMULATIONS SHOWING DEGREE OF DISPERSION OVER TIME
  • Figures 9, 10 and 11 show Budesonide 160µg/shot, Formoterol 4.5µg/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 15, 30, and 60 seconds standing time.
  • Figures 12, 13 and 14 shows Budesonide 80µg/shot, Formoterol 4.5µg/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 30, and 60 seconds standing time.
    • TABLE OF DEGREEE OF DISPERSION OF SUSPENSIONS OVER TIME: (ALL SAMPLES)
  • Photographs were taken of all doses (320µg/4.5µg to 40µg/4.5µg) at 0, 15, 30, 60, 90 seconds, and 2, 5 and 10 minutes. As this produced too many photographs to reproduce here, a chart has been constructed to give a reprentation of the degree of dispersion over time.
    If the sample was fully suspended, the sample was rated 0 e.g. at 0 minutes they were fully dispersed. From there, the samples have been rated in increments of I-5 at 20% intervals to express the degree of dispersion i.e. 0 was fully suspended and 5 fully creamed. This allows some comparison across the whole dose range and PVP concentration range used.
    (Note concentration of Formoterol is 4.5µg/shot in all the samples)
    (Samples are all fully dispersed at 0 seconds and therefore all have a score of 0) Fully dispersed - 0
    More than 80% dispersed ie less than 20% clear liquid present 1
    More than 60% dispersed ie less than 40% clear liquid present 2
    Less than 40% dispersed ie more than 60% clear liquid present 3
    Less than 20% dispersed ie more than 80% clear liquid present 4
    Fully creamed 5 TABLE OF DEGREEE OF DISPERSION OF SUSPENSIONS OVER TIME: ALL SAMPLES
    Dose Time PVP concentration (% w/w)
    µg/shot Budesonide Sec/mins 0.0001 0.0005 0.001 0.01 0.03 0.05
    320 15 2 1 0-1 0-1 0-1 0-1
    30 3 3 2 1-2 2 2
    60 4 4 3-4 2 3 3-4
    90 4 5 5 3 5 5
    2 5 5 4-5 4-5 5 5
    5 5 5 5 5 5 5
    10 5 5 5 5 5 5
    160 15 3 2 0-1 0-1 2 2
    30 3 2 1 1 2 2
    60 5 4 1 2 4 5
    90 5 5 1 2 5 5
    2 5 5 1 2 5 5
    5 5 5 2 4 5 5
    10 5 5 2 4 5 5
    80 15 2 1 0 0 1 1
    30 3 2 1 1 2 2
    60 4 2 1 1-2 3 3
    90 5 3 1-2 1-2 4 3
    2 5 3-4 1 1 5 4
    5 5 4 2 2 5 5
    10 5 5 3 3 5 5
    40 15 1 1 0 0 1 2
    30 2 1 1 2 2 3
    60 1-2 1 1 2 2 3
    90 1-2 1-2 1-2 2 2-3 4
    2 2 2 2 3 4 5
    5 3 2 2 3 4 5
    10 4-5 3 2 4 5 5
  • Suspensions considered excellent are highlighted in bold.
    It can be seen that the formulations with 0.001% w/w PVP gave the best suspension stability overall.
    • OSCAR DATA (Graphs of light transmission versus time)
  • Figure 2 shows the average OSCAR transmission readings (lower sensor only) for various concentrations of PVP K25. A low transmission reading indicates that the suspension is dispersed preventing light being transmitted. Hence, it can be seen that the lowest line is the most stable formulation. This is the 0.001% PVP sample.
  • In Figure 3, the bottom line, again with low transmission readings, clearly shows that the formulation containing 0.001% PVP is the most stable.
    • TURBISCAN DATA(Graphs of percentage (%) light transmission versus time)
  • Data from the Turbiscan can be intepretated in a similar vein to the OSCAR data in that a low percentage (%) transmission indicates the suspension is dispersed . The % transmission averages quoted here were taken from a zone around the middle of the suspension sample. In Figure 4 the most stable formulation is the lowest line with the lowest % transmission, i.e. the bold black line with 0.001%w/w PVP
  • Figures 5 and 6 show that the suspension with 0.001% w/w PVP is the most stable (bottom bold line) with the lowest % transmission.
    • FURTHER EVALUATION: Determination of the optimum PEG 1000 concentration.
  • For this evaluation, photography, turbiscan and force to fire data (valve performance) was used to determine the optimum PEG concentration.
    • METHODOLOGY - Force to fire (return force at 0.5mm stem return)
  • Force to fire testing was performed using the Lloyd LRX testing machine. The pMDI unit to be tested was placed valve down in a can holder on the lower platform of the unit. The upper crosshead was then moved to just above the base of the can. Can actuations were performed using a standard protocol. During measurement, force data is captured by means of the load cell located at the top of the upper crosshead. This program was designed to output the return force at 0.5mm stem return as this is the point at which the metering chamber is considered to refill.
    A low return force is indicative of high friction and potential sticking problems. It also suggests there may be a problem with low actuation weights as the propellant enters the metering chamber more slowly and has time to vaporise. Force to fire testing was performed at preset actuations.
    • DATA FORCE TO FIRE DATA
  • Figure 7 shows the effect of PEG 1000 concentration on stem return force for the 4.5/160 µg formoterol/budesonide formulation
  • This shows that at 120 actuations, the return force is greater for the 0.3% w/w PEG 1000 concentration than for the other concentrations of 0.5% and 0.1 %. In general, the higher the return force the lesser the chance of the valve stem sticking. The above data shows that in this case 0.3% would be preferred.
    • TURBISCAN DATA
  • The Turbiscan data (figure 8) shows that there is little difference between the stability of suspensions made with varying levels of PEG 1000 except for the 0.005% w/w level which was unsatisfactory.
    • PHOTOGRAPHIC ANALYSIS
  • Digital photographs of suspensions containing Budesonide, Formoterol, HFA 227, 0.001%w/w PVP and varying levels of PEG 1000 show little variation in suspension stability over time (0 seconds to 10 minutes) except for the 0.005% w/w PEG level (in agreement with the Turbiscan data).
  • Figures 15 and 16 show Budesonide 80µg/shot, Formoterol 4.5µg/shot with 0.001% PVP K25 and various concentrations of PEG 1000 at 0 (1) and 10 minutes (2) standing time
    • PRODUCT PERFORMANCE DATA
  • In addition to the above, product performance data for formulations containing formoterol fumurate dihydrate/budesonide at the following strengths, 4.5/80 mcg per actuation and 4.5/160 mcg per actuation, with 0.001% PVP K25 and either 0.1% or 0.3% PEG 1000 were stable for up to 12 months at 25°C/60% RH.
    • Product performance data for Symbicort formulations containing 0.001% PVP K25 and 0.1% PEG 1000 in HFA-227
  • Product strength (µg) (FFD/budesonide) Fine particle fraction (% cumulative undersize for 4.7 µm cut-off)
    Drug Initial 25°C/60% RH 6 months 25°C/60% RH 12 months
    4.5/80 Budesonide 51.3 52.8 62.0
    FFD 55.4 53.5 59.7
    4.5/160 Budesonide 50.0 48.8 47.0
    FFD 54.2 52.1 51.3
    • Product performance data for Symbicort formulations containing 0.001% PVP K25 and 0.3% PEG 1000 in HFA-227
  • Product strength (µg) (FFD/budesonide) Fine particle fraction (% cumulative undersize for 4.7 µm cut-off)
    Drug Initial 23°C/60%RH 6 months 25°C/60% RH 12 months
    4.5/80 Budesonide 55.8 50.6 51.3
    FFD 64.2 57.6 58.7
    4.5/160 Budesonide 48.7 50.2 52.3
    FFD 55.6 59.1 61.2

Claims (13)

  1. A pharmaceutical composition comprising formoterol, budesonide, HFA 227, PVP and PEG, in which the PVP is present in an amount of 0.001% w/w.
  2. A pharmaceutical composition according to claim 1 in which the PVP is PVP K25.
  3. A pharmaceutical composition according to claim 1 or claim 2 in which the PEG is PEG 1000.
  4. A pharmaceutical composition according to any one of claims 1 to 3 in which formoterol is in the form of its fumarate dihydrate salt
  5. A pharmaceutical composition according to any one of claims 1 to 4 in which the formoterol is in the form of the single R, R-enantiomer.
  6. A pharmaceutical composition according to any one of claims 1 to 5 in which the second active ingredient is the 22R-epimer of budesonide.
  7. A pharmaceutical composition according to any one of claims 1 to 6 for use for the treatment or prophylaxis of a respiratory disorder.
  8. A pharmaceutical composition according to any one of claims 1 to 6 for use for the treatment or prophylaxis of asthma, rhinitis or COPD.
  9. Use of a pharmaceutical composition according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of a respiratory disorder in a mammal.
  10. Use of a pharmaceutical composition according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of asthma, rhinitis or COPD.
  11. Use of a pharmaceutical composition according to any one of claims 1 to 6 in the manufacture of a medicament for inhalation from a MDI device, for the treatment of asthma, rhinitis or COPD.
  12. A metered dose inhaler device containing a pharmaceutical composition according to any one of claims 1 to 6.
  13. The metered dose inhaler device according to claim 12 which delivers the formoterol/budesonide at 4.5/80 mcg or 4.5/160 mcg per actuation.
EP08166881A 2002-02-01 2003-01-29 Novel Composition Expired - Lifetime EP2036549B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200331805T SI2036549T1 (en) 2002-02-01 2003-01-29 Novel Composition
CY20101100546T CY1110081T1 (en) 2002-02-01 2010-06-14 new composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200312A SE0200312D0 (en) 2002-02-01 2002-02-01 Novel composition
EP03703575A EP1474117B1 (en) 2002-02-01 2003-01-29 Composition for inhalation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP03703575.5 Division 2003-01-29
EP03703575A Division EP1474117B1 (en) 2002-02-01 2003-01-29 Composition for inhalation

Publications (2)

Publication Number Publication Date
EP2036549A1 EP2036549A1 (en) 2009-03-18
EP2036549B1 true EP2036549B1 (en) 2010-04-07

Family

ID=20286853

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03703575A Revoked EP1474117B1 (en) 2002-02-01 2003-01-29 Composition for inhalation
EP08166881A Expired - Lifetime EP2036549B1 (en) 2002-02-01 2003-01-29 Novel Composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03703575A Revoked EP1474117B1 (en) 2002-02-01 2003-01-29 Composition for inhalation

Country Status (27)

Country Link
US (8) US7759328B2 (en)
EP (2) EP1474117B1 (en)
JP (2) JP2005521663A (en)
KR (2) KR100947168B1 (en)
CN (1) CN1287774C (en)
AT (2) ATE423552T1 (en)
AU (1) AU2003206289B2 (en)
BR (1) BR0307193A (en)
CA (1) CA2474479C (en)
CO (1) CO5611098A2 (en)
CY (2) CY1109030T1 (en)
DE (2) DE60326320D1 (en)
DK (2) DK2036549T3 (en)
ES (2) ES2321180T3 (en)
IL (1) IL163160A (en)
IS (2) IS7360A (en)
MX (1) MXPA04007295A (en)
NO (1) NO337006B1 (en)
NZ (1) NZ534452A (en)
PL (1) PL211836B1 (en)
PT (2) PT1474117E (en)
RU (1) RU2301673C2 (en)
SE (1) SE0200312D0 (en)
SI (2) SI2036549T1 (en)
UA (1) UA79445C2 (en)
WO (1) WO2003063842A1 (en)
ZA (1) ZA200406086B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200312D0 (en) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
MX2007009698A (en) * 2005-02-11 2007-09-26 Argenta Discovery Ltd Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases.
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
DE102006053374A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation for aerosols with two or more active substances and at least one surface-active substance
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
US20130160761A1 (en) * 2008-11-04 2013-06-27 Cipla Limited Pharmaceutical Aerosol Composition
NZ574666A (en) 2009-02-05 2009-04-30 Nexus6 Ltd A medicament inhaler holder that uses optical means to count and display the number of doses used
EP2414560B1 (en) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Method for coating a surface of a component
EP3508239B1 (en) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalant apparatus and atomizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
MX2012005961A (en) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizer.
JP5658268B2 (en) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
JP5874724B2 (en) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
JP2013531056A (en) * 2010-07-16 2013-08-01 シプラ・リミテッド A pharmaceutical composition comprising R (+) budesonide and one or more bronchodilators
EP3143987A1 (en) * 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
EP2618816A4 (en) * 2010-09-22 2014-10-29 Map Pharmaceuticals Ltd Aerosol composition for administering drugs
US20120204871A1 (en) 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
TWI399202B (en) * 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
BR112014003907A2 (en) 2011-08-19 2017-06-13 Intech Biopharm Ltd. Method for preparing metered dose powdered inhaler to treat respiratory disease
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
BR122022010094B1 (en) 2014-05-07 2023-10-03 Boehringer Ingelheim International Gmbh INDICATING DEVICE AND CONTAINER
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
MX383195B (en) 2014-05-07 2025-03-13 Boehringer Ingelheim Int CONTAINER, NEBULIZER AND USE.
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN106581010B (en) * 2016-12-28 2019-03-05 四川普锐特医药科技有限责任公司 A kind of aerosol preparation and metered dose inhalation aerosol
CA3073195A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
JP7470646B2 (en) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド Methods for treating and preventing asthma symptoms with corticosteroid pharmaceutical compositions - Patents.com
JP7402631B2 (en) 2018-08-27 2023-12-21 帝人株式会社 Ultrafine carbon fiber mixture, manufacturing method thereof, and carbon-based conductive aid
CN109464429B (en) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 Inhalation pressure quantitative aerosol pharmaceutical composition and preparation method thereof
CN112137957B (en) 2019-06-26 2022-07-29 长风药业股份有限公司 Medicinal inhalation aerosol and preparation method thereof
CN112972384B (en) * 2019-12-02 2022-03-18 长风药业股份有限公司 Preparation method of glycopyrronium bromide and indacaterol bulk drug micro-powder mixture
CN117357485B (en) * 2023-11-01 2024-09-24 山东京卫制药有限公司 Improved inhalable carrier particles and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US6123924A (en) * 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
DE19536902A1 (en) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Miniature fluid pressure generating device
SE9603669D0 (en) 1996-10-08 1996-10-08 Astra Ab New combination
EP0938467B1 (en) * 1996-11-11 2002-06-12 Sepracor, Inc. Process for the preparation of optically pure isomers of formoterol
SE9703407D0 (en) 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9802073D0 (en) * 1998-06-11 1998-06-11 Astra Ab New use
ATE283033T1 (en) 1998-07-24 2004-12-15 Jago Res Ag MEDICAL AEROSOL FORMULATIONS
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
PE20011227A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
SE0200312D0 (en) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
RU2301673C2 (en) 2007-06-27
US10166247B2 (en) 2019-01-01
EP1474117A1 (en) 2004-11-10
CY1109030T1 (en) 2014-07-02
DE60326320D1 (en) 2009-04-09
UA79445C2 (en) 2007-06-25
SE0200312D0 (en) 2002-02-01
US20050089478A1 (en) 2005-04-28
RU2004122921A (en) 2005-06-10
HK1126684A1 (en) 2009-09-11
SI2036549T1 (en) 2010-07-30
JP5259636B2 (en) 2013-08-07
MXPA04007295A (en) 2004-10-29
PL211836B1 (en) 2012-06-29
IL163160A (en) 2013-12-31
WO2003063842A1 (en) 2003-08-07
US20210069215A1 (en) 2021-03-11
DK1474117T3 (en) 2009-05-25
US7759328B2 (en) 2010-07-20
ES2321180T3 (en) 2009-06-03
NO20043458L (en) 2004-08-19
KR20040081757A (en) 2004-09-22
US8143239B2 (en) 2012-03-27
ATE463241T1 (en) 2010-04-15
CA2474479A1 (en) 2003-08-07
US20120216802A1 (en) 2012-08-30
DE60332067D1 (en) 2010-05-20
US20190216828A1 (en) 2019-07-18
US20170368078A1 (en) 2017-12-28
BR0307193A (en) 2004-11-03
US20100275913A1 (en) 2010-11-04
WO2003063842A9 (en) 2004-04-22
JP2010132695A (en) 2010-06-17
ES2342509T3 (en) 2010-07-07
PT1474117E (en) 2009-04-24
CO5611098A2 (en) 2006-02-28
NZ534452A (en) 2006-01-27
JP2005521663A (en) 2005-07-21
US20160022703A1 (en) 2016-01-28
ZA200406086B (en) 2006-01-25
US20140286878A1 (en) 2014-09-25
CN1287774C (en) 2006-12-06
CN1625392A (en) 2005-06-08
DK2036549T3 (en) 2010-07-12
NO337006B1 (en) 2015-12-21
EP1474117B1 (en) 2009-02-25
CY1110081T1 (en) 2015-01-14
IS7360A (en) 2004-07-21
IS2960B (en) 2017-02-15
US11311558B2 (en) 2022-04-26
KR20090125857A (en) 2009-12-07
PL372118A1 (en) 2005-07-11
AU2003206289B2 (en) 2007-09-06
KR100947168B1 (en) 2010-03-12
IS9028A (en) 2013-04-16
CA2474479C (en) 2011-04-05
US8575137B2 (en) 2013-11-05
SI1474117T1 (en) 2009-06-30
EP2036549A1 (en) 2009-03-18
PT2036549E (en) 2010-06-22
ATE423552T1 (en) 2009-03-15

Similar Documents

Publication Publication Date Title
US11311558B2 (en) Composition for inhalation
AU2003206289A1 (en) Composition for inhalation
EP2488157B1 (en) Improved formulations
HK1126684B (en) Novel composition
AU2013203244B2 (en) Improved formulations
HK1173076B (en) Improved formulations
HK1173076A (en) Improved formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081017

AC Divisional application: reference to earlier application

Ref document number: 1474117

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20090427

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126684

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AXX Extension fees paid

Extension state: LT

Payment date: 20081017

Extension state: AL

Payment date: 20081017

Extension state: RO

Payment date: 20081017

Extension state: MK

Payment date: 20081017

Extension state: LV

Payment date: 20081017

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1474117

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60332067

Country of ref document: DE

Date of ref document: 20100520

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100614

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2342509

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100401359

Country of ref document: GR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E004291

Country of ref document: EE

Effective date: 20100610

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 7365

Country of ref document: SK

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1126684

Country of ref document: HK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110110

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E009233

Country of ref document: HU

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20151209

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170131

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20211214

Year of fee payment: 20

Ref country code: SK

Payment date: 20211214

Year of fee payment: 20

Ref country code: SE

Payment date: 20211210

Year of fee payment: 20

Ref country code: IE

Payment date: 20211209

Year of fee payment: 20

Ref country code: GB

Payment date: 20211209

Year of fee payment: 20

Ref country code: FR

Payment date: 20211217

Year of fee payment: 20

Ref country code: EE

Payment date: 20211227

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20211217

Year of fee payment: 20

Ref country code: CH

Payment date: 20211216

Year of fee payment: 20

Ref country code: BE

Payment date: 20211221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20211216

Year of fee payment: 20

Ref country code: LU

Payment date: 20220110

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20211212

Year of fee payment: 20

Ref country code: FI

Payment date: 20220110

Year of fee payment: 20

Ref country code: DK

Payment date: 20220110

Year of fee payment: 20

Ref country code: DE

Payment date: 20211207

Year of fee payment: 20

Ref country code: AT

Payment date: 20211229

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220127

Year of fee payment: 20

Ref country code: PT

Payment date: 20220128

Year of fee payment: 20

Ref country code: IT

Payment date: 20211213

Year of fee payment: 20

Ref country code: ES

Payment date: 20220203

Year of fee payment: 20

Ref country code: CZ

Payment date: 20220114

Year of fee payment: 20

Ref country code: CY

Payment date: 20220128

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20211216

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60332067

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20230129

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20230128

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20230129

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9A

Effective date: 20230129

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230128

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 7365

Country of ref document: SK

Expiry date: 20230129

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 463241

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230129

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230208

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230129

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230129

Ref country code: SI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230130

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230128

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E004291

Country of ref document: EE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230130